Phenibut: The Legal Supplement Causing Hospitalizations

Phenibut (β-phenyl-γ-aminobutyric acid) is not really a supplement. It is a prescription medication in some countries that has been quietly sold online to people in countries where it is not approved at all. Despite being marketed as a "calming nootropic" or "natural anxiety aid," phenibut is pharmacologically closer to a benzodiazepine than to any vitamin or herb — and it carries the kinds of risks you would expect from that comparison.

What Phenibut Is

Phenibut was developed in the Soviet Union in the 1960s and is still prescribed in Russia, Ukraine, Belarus, and Latvia for anxiety, sleep disorders, and certain post-stroke and post-traumatic conditions. It has never been approved by the U.S. FDA, Health Canada, the UK MHRA, or Australia's TGA. In the United States it sits in a gap: not approved as a drug, never properly classified as a dietary supplement either — but also not federally scheduled, which has let online sellers offer it for years.

How It Works

Phenibut is a GABA-B receptor agonist, like the prescription muscle relaxant baclofen. It also weakly activates GABA-A receptors and modulates voltage-gated calcium channels at higher doses. Adding the phenyl ring lets it cross the blood-brain barrier in a way that ordinary GABA cannot. At 250–750 mg, users typically describe feelings of calm, reduced social anxiety, and mild euphoria. At higher doses the effects look more like alcohol or benzodiazepines: heavy sedation, slurred speech, slowed breathing, and impaired coordination.

The Dependence and Withdrawal Problem

Phenibut's most documented harm is rapid physical dependence. Case reports describe tolerance building within just a few days of daily use, and clinically significant withdrawal after as little as one to two weeks of regular dosing. Withdrawal symptoms include severe rebound anxiety, insomnia, tremor, hallucinations, and psychosis. Unlike caffeine withdrawal, phenibut withdrawal can be medically serious. Hospitalized patients are typically managed with long-acting benzodiazepines (similar to alcohol or benzodiazepine withdrawal) and slow phenibut tapers over weeks.

What the Surveillance Data Show

A 2020 MMWR report by Graves and colleagues analyzed phenibut exposures reported to U.S. poison control centers between 2009 and 2019. Calls increased sharply over the decade. Many cases were severe enough to be coded as "major" outcomes — including respiratory depression, agitated delirium, and intensive-care admissions. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the World Health Organization Expert Committee on Drug Dependence have both flagged phenibut as a substance of growing concern.

Where Authorities Now Stand

• Australia. Phenibut was placed on Schedule 9 (Prohibited Substance) by the TGA in 2018, making non-medical possession illegal.
• United States. The FDA issued a warning letter campaign in 2019 telling companies that phenibut does not qualify as a dietary supplement under DSHEA. Several states (Alabama, Louisiana, others) have since scheduled it at the state level.
• United Kingdom. Phenibut is covered under the Psychoactive Substances Act 2016, which bans production and supply for human consumption; the UK Advisory Council on the Misuse of Drugs has reviewed it for tighter scheduling.
• Canada. Health Canada has not approved phenibut as a drug and has issued advisories against unauthorized health products containing it.
• Russia/Ukraine. Available by prescription only, with growing concern about misuse even where it is approved.

Bottom Line

Phenibut is not a benign anxiety aid. It is a centrally active GABAergic drug with a rapid dependence profile and a withdrawal syndrome serious enough to require hospitalization. Because it acts on the same receptor families as alcohol and benzodiazepines, mixing it with either dramatically raises the risk of respiratory depression. There is no safe casual-use protocol for phenibut. Anyone who has been taking it daily should not stop abruptly; a medically supervised taper is the safer way out.

If you are looking for the calming, social-anxiety-reducing effects people describe with phenibut, the safer evidence-based options are: short-term cognitive behavioral therapy, prescription SSRIs/SNRIs, or, for situational use under a clinician's care, beta blockers. Glycine, magnesium, and L-theanine have far smaller effects but no comparable risk profile.